Otsuka Holdings Co., Ltd.

Equities

4578

JP3188220002

Pharmaceuticals

Delayed Japan Exchange 12:12:53 2024-04-16 am EDT 5-day change 1st Jan Change
6,296 JPY -0.79% Intraday chart for Otsuka Holdings Co., Ltd. +0.49% +19.00%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
H. Lundbeck, Otsuka Pharmaceutical Seek US FDA Nod for PTSD Combination Therapy MT
Otsuka Holdings Disposes of 2.32 Billion Yen Worth of Shares as Restricted Stock Compensation MT
EU Commission Green-lights Lundbeck, Otsuka's Abilify Maintena as Maintenance Treatment of Schizophrenia MT
Jefferies Adjusts Otsuka Holdings’ Price Target to 7,400 Yen From 6,800 Yen, Keeps at Buy MT
Sumitomo Pharma Amends Collaboration Agreement with Otsuka Pharmaceutical MT
VIE STYLE, Inc. announced that it has received ¥305 million in funding from Otsuka Holdings Co., Ltd., KAYAC Inc., Taisho Pharmaceutical Holdings Co., Ltd., Towa Pharmaceutical Co., Ltd., PE&HR Co., Ltd., Murata Manufacturing Co., Ltd. and other investors CI
IBio Sells Preclinical PD-1 Antagonist Antibody Program to Otsuka DJ
Otsuka Holdings' Attributable Profit Down 9.2% 2023 On Impairment Losses MT
Otsuka Holdings Co., Ltd. Provides Year-End Dividend Guidance for the Fiscal Year Ending December 31, 2024 CI
Otsuka Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the First Half and Full Year of Fiscal Year Ending December 31, 2024 CI
Otsuka Holdings Co., Ltd. Announces Year-End Dividend for the Year Ended December 31, 2023, Payable on March 29 , 2024; Provides Second Quarter-End Dividend Guidance for the Fiscal Year 2024 CI
Otsuka Holdings Lowers 2023 Profit Outlook MT
Japan's Nikkei cruises to 34-year peak, briefly breaching 38,000 range RE
Japan's Nikkei soars to 34-year high on chip shares, earnings RE
Phase 3 Trial for Otsuka's Alzheimer's-related Agitation Treatment Fails to Meet Primary Endpoint MT
Otsuka's drug for Alzheimer's disease agitation fails in late stage study RE
Otsuka Holdings Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ended December 31, 2023 CI
Ionis Pharmaceuticals Says Potential Angioedema Treatment Met Primary Endpoint of Phase 3 Study MT
Ionis Pharmaceuticals Signs Europe Licensing Deal With Otsuka for Donidalorsen in Hereditary Angioedema MT
Otsuka's Unit Remains as MicroPort Scientific's Thai Distributor Until 2026 MT
Otsuka Unit Buys New York-Based Provider of Women Health Products MT
Nomura Adjusts Otsuka Holdings' Price Target to 6,800 Yen From 6,500 Yen, Keeps at Buy MT
Jefferies: Investor Interest Shifts from Daiichi Sankyo to Chugai and Otsuka Holdings MT
US FDA approves Medtronic's blood pressure treatment device for use RE
Aurinia Pharmaceuticals Partner Otsuka Pharmaceutical Files New Drug Application For Voclosporin in Japan MT
Chart Otsuka Holdings Co., Ltd.
More charts
Otsuka Holdings Co, Ltd. is a holding company organised around 4 areas of activity: - manufacture and sale of pharmaceutical products (65.2% of sales): prescription drugs and intravenous solutions mainly for the treatment of central nervous system disorders, cancer, cardiovascular, gastrointestinal and ophthalmic diseases. In addition, the group sells diagnostic products and medical devices; - manufacture and sale of nutraceutical products (25.1%): functional foods and beverages, OTC products, nutritional supplements; - production of mineral waters, beverages and foods (2.1%); - other (7.5%): manufacture of functional chemicals and fine chemicals, provision of logistics services, manufacture of electronic products, etc. Net sales by source of income are divided between sales of products (93.8%), sales of licences and royalties (1.8%) and other (4.4%). Net sales are distributed geographically as follows: Japan (43.2%), North America (34%),
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
11
Last Close Price
6,346 JPY
Average target price
5,982 JPY
Spread / Average Target
-5.74%
Consensus
  1. Stock Market
  2. Equities
  3. 4578 Stock
  4. News Otsuka Holdings Co., Ltd.
  5. Otsuka Schedules Restricted Stock Compensation